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A	FLIP	OF	A	COIN?	
	
LONG-TERM	RETENTION	IN	OFFICE	BASED	
	
OPIOID	TREATMENT	WITH	BUPRENORPHINE	
	
ZOE	MARGARET	WEINSTEIN	
	
ABSTRACT	
	
Background:	Guidelines	recommend	long-term	treatment	for	opioid	use	disorder	
including	the	use	of	buprenorphine;	however,	little	is	known	about	patients	in	long-term	
treatment.	
Objective:	Examine	the	prevalence	and	patient	characteristics	associated	with	long-term	
treatment	retention	(≥1	year)	in	an	Office	Based	Opioid	Treatment	(OBOT)	program	with	
buprenorphine.	
Study	Design:	This	is	a	12-year	retrospective	cohort	study	of	adults	on	buprenorphine	in	
OBOT	in	a	large	urban	safety-net	primary	care	practice.		
Methods:	The	primary	outcome	was	retention	in	OBOT	for	≥1	continuous	year.	Patients	
who	re-enrolled	multiple	times	in	the	program	contributed	repeated	observations.	
Potential	predictors	of	≥1	year	retention	assessed	were:	age,	race/ethnicity,	psychiatric	
diagnoses,	hepatitis	C,	employment,	prior	buprenorphine,	ever	heroin	use,	current	
cocaine,	benzodiazepine	and	alcohol	use	on	enrollment.	Factors	associated	with	≥1	year	
OBOT	retention	were	identified	using	generalized	estimating	equation	logistic	
regression	models.	The	different	reasons	for	clinic	disengagement	by	retention	status	
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(i.e.	≥1	year	vs.	<1	year)	were	also	described.	
Results:		OBOT	treatment	periods	(n=1605)	among	1237	patients	were	assessed.	Almost	
half,	44.7%	(717/1605),	of	all	treatment	periods	were	≥1	year	and	a	majority,	53.7%	
(664/1237),	of	patients	had	at	least	one	≥	1	year	period.	In	adjusted	analyses,	female	
gender	(Adjusted	Odds	Ratio	[AOR]	1.55,	95%	CI	[1.20,	2.00])	psychiatric	diagnosis	(AOR	
1.75	[1.35,	2.27])	and	age	(AOR	1.19	per	10	year	increase	[1.05,	1.34])	were	associated	
with	greater	odds	of	≥1	year	retention.		Unemployment	(AOR	0.72		[0.56,	0.92]),	
Hepatitis	C	(AOR	0.59	[0.45,	0.76]),	black	race/ethnicity	(AOR	0.53		[0.36,	0.78])	and	
Hispanic	race/ethnicity	(AOR	0.66		[0.48,	0.92]),	compared	to	white,	were	associated	
with	lower	odds	of	≥1	year	retention.	Relapse	to	substance	use	appeared	to	be	a	less	
common	reason	for	disengagement	for	the	≥1	year	(23.3%)	compared	to	the	<1	year	
(40.1%)	treatment	periods.	
Conclusions:	Over	half	of	patients	were	successfully	retained	in	Office	Based	Opioid	
Treatment	with	buprenorphine	for	≥1	year.	However,	significant	disparities	in	one-year	
treatment	retention	were	seen,	including	poorer	retention	for	patients	who	were	
younger,	black,	Hispanic,	unemployed,	or	with	hepatitis	C.	
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INTRODUCTION	
Buprenorphine	is	an	effective	treatment	for	opioid	use	disorder	(OUD)	but	short-
term	medication	alone	is	not	sufficient	for	long-term	recovery	from	OUD.1,2	According	to	
the	American	Society	of	Addiction	Medicine,	for	patients	with	OUD	the	standard	of	care	
is		“long-term	or	even	lifetime	medication	use.”1	Unfortunately,	in	most	studies	less	
than	two-thirds	of	patients	who	enroll	in	Office	Based	Opioid	Treatment	(OBOT)	with	
buprenorphine	stay	in	treatment	for	greater	than	six	months	3,4,5	and	much	of	the	
previous	research	on	OBOT	has	focused	on	buprenorphine	induction	and	short-term	
treatment	retention.	This	study	is	uniquely	poised	to	describe	the	growing	but	
understudied	population	of	patients	who	are	engaged	in	long-term	buprenorphine	
treatment	and	risk	factors	for	disenrollment	from	this	lifesaving	and	cost-saving	
treatment.	These	findings	explore	important	prognostic	and	management	questions	for	
patients	and	providers,	as	well	as	guide	future	policy	on	possible	interventions	to	better	
maintain	patients	in	treatment.	
BACKGROUND:	
	Opioid	use	disorder	(OUD)	is	both	a	highly	prevalent	disease	and	one	associated	
with	high	morbidity	and	mortality.	An	estimated	6.9	million	Americans	met	criteria	for	a	
substance	use	disorder	in	2013;	however,	unfortunately	only	917,000	(13.4%)	of	these	
individuals	received	any	kind	of	substance	use	treatment	in	the	year	2013	according	to	
the	National	Survey	on	Drug	Use	and	Health.6	This	low	rate	of	treatment	is	despite	the	
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fact	that	currently	there	are	multiple	effective	treatment	options	available	in	the	United	
States	for	OUD,	including	the	medication	buprenorphine.			
OUD	is	such	a	devastating	disease	that	in	2013	the	Department	of	Health	and	
Human	Services	declared	opioid	overdose	deaths	an	epidemic.7,8	However	it	is	a	
treatable	condition,	with	the	mainstay	of	treatment	being	Medication	Assisted	
Treatment	(MAT),	a	combination	of	the	medication	(typically	either	methadone	or	
buprenorphine)	and	relapse	prevention	counseling.	MAT	has	been	shown	to	be	a	truly	
lifesaving	treatment	9,	and	Dr.	Nora	Volkow,	the	Director	of	the	National	Institute	on	
Drug	Abuse	(NIDA)	at	the	National	Institutes	of	Health,	has	strongly	supported	increased	
use	of	MAT10.	
OUD	is	also	a	costly	disease,	with	illicit	drug	use	costing	the	Unites	States	$194	
billion	in	2011,	including	the	cost	of	medical	complications,	lost	wages	and	
incarceration11.		In	the	past	decades	there	have	been	many	studies	that	demonstrate	
treatment	is	cost-saving,	as	patients	with	OUD	who	are	engaged	in	outpatient	treatment	
have	decreased	healthcare	utilization.	In	a	large	retrospective	claims	database	analysis	
of	patients	with	OUD,	being	on	agonist	treatment	and	receiving	medication	was	
associated	with	fewer	inpatient	admissions	of	all	types,	not	just	for	SUD	related	disease	
or	complications.12	An	analysis	of	Medicaid	patients’	health	care	utilization	and	cost	
before	and	after	engaging	in	outpatient	treatment	with	MAT,	showed	a	decline	in	the	
number	inpatient	days,	and	emergency	room	visits	for	patients	engaged	in	outpatient	
treatment.	Notably	this	study	also	showed	there	was	a	significant	improvement	in	
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morbidity	and	mortality	after	engaging	in	treatment.13	Given	the	wide	range	of	benefits	
of	treatment,	it	is	more	important	than	ever	that	we	ensure	as	many	patients	as	
possible	engage	in	treatment	and	remain	in	treatment.	While	there	is	a	broad	literature	
on	the	benefit	of	MAT,	most	of	this	literature	focuses	on	early	engagement,	and	the	
earliest	medication	for	MAT,	methadone.		
Buprenorphine,	a	partial	mu	opioid	agonist,	is	a	relatively	new	medication	for	
the	treatment	of	OUD,	only	approved	by	the	Food	and	Drug	Administration	since	2002.	
Buprenorphine	is	also	well	established	to	be	equally	effective	when	compared	to	
methadone,	and	some	studies	suggest	buprenorphine	is	superior	in	inducing	complete	
abstinence	from	illicit	opiates,	however	these	effects	are	dependent	on	continued	
treatment.14,15	Additionally	buprenorphine	has	been	demonstrated	in	many	studies	to	
be	effective	in	preventing	relapse	as	well	as	death.1,16		Although	buprenorphine	has	now	
been	available	in	the	United	States	for	over	a	decade,	and	long-term	treatment	is	the	
standard	of	care	according	to	the	American	Society	of	Addiction	Medicine1,	little	is	
known	about	patients	who	are	in	long-term	(greater	than	1	year)	buprenorphine	
treatment.	
Unfortunately,	in	most	studies	less	than	two-thirds	of	patients	who	enroll	in	
Office	Based	Opioid	Treatment	(OBOT)	with	buprenorphine	stay	in	treatment	for	greater	
than	six	months.3,4,5	Patient-specific	factors	that	lead	to	early	(i.e.	within	six	months)	
patient	disengagement	from	OBOT	have	been	found	to	be	related	to	a	patient’s	inability	
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to	adhere	to	the	structure	of	the	clinic	3,17	or	to	continued	polysubstance	or	illicit	opioid	
use.15,18,19	To	assess	for	patient’s	ability	to	adhere	to	clinic	structure,	Tkacz	et	al.	
reviewed	patient	reports	of	medication	adherence	and	relapse	for	702	patients	newly	
initiating	on	buprenorphine	at	1,2	and	3	month	follow-up.17	Gryczynski	et	al.	reviewed	
interviews	with	297	African	American	patients	starting	on	buprenorphine	treatment	at	3	
and	6	months	as	part	of	a	larger	randomized	control	trial.		The	majority	of	patients	
(58%)	who	left	within	the	first	6	months	left	treatment	due	to	disagreement	with	staff,	
missing	too	many	days	or	reporting	that	the	program	conflicted	too	much	with	their	
life.3	
	Multiple	studies	have	confirmed	that	patients	using	illicit	buprenorphine	at	
OBOT	enrollment	have	increased	short-term	retention	in	buprenorphine	treatment4,20.	
Once	enrolled	in	OBOT	with	buprenorphine,	illicit	benzodiazepine19	and	illicit	opioid21,22	
use	early	in	treatment	are	both	predictive	of	short-term	disengagement.	Some	studies	
show	that	cocaine	use	is	associated	with	short-term	disengagement3,23	while	others	
show	no	effect	24.		Of	note,	the	Schottenfeld	et	al.	study	included	only	patients	with	
both	opioid	dependence	and	cocaine	dependence	or	abuse,	as	one	aim	of	their	study	
was	to	assess	whether	buprenorphine	was	superior	to	methadone	in	reducing	cocaine	
use,	and	thus	likely	represented	a	sample	with	more	significant	cocaine	use	than	most	
patient	samples.24	
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Additionally,	some	patient	demographic	characteristics	have	also	been	shown	to	
be	predictive	of	short-term	treatment	retention,	including	white	race	15,	older	age15,3	
employment21	and	lack	of	psychiatric	comorbidity.18,19	Some	of	these	studies	were	
randomized	control	trials	comparing	buprenorphine	and	methadone	maintenance3,15.	
Given	the	additional	support	and	patient	contact	inherent	in	a	randomized	trial,	these	
studies	may	not	be	as	reflective	of	patients’	real-world	patient	trajectories	as	in	our	
current	study.	Other	studies	were	limited	by	their	small	sample	size,	for	example,	
Fareed	et	al.	examined	only	69	patients,	while	Ferri	et	al.’s	sample	size	was	62	patients.	
Additionally	others	were	limited	in	generalizability,	for	example	in	the	Fareed	et	al.	
study	only	a	third	(33%)	of	the	patients	ever	used	heroin	and	none	had	a	urine	drug	test	
positive	for	cocaine	during	a	random	call	back,	indicating	less	poly-substance	use	and	
perhaps	less	severe	addiction	compared	to	an	urban	safety-net	sample.18	
	Notably	however,	few	of	these	studies	address	long-term	treatment	(i.e.	
patients	established	in	buprenorphine	treatment	for	greater	than	one	year),	and	thus	
little	is	known	about	patients	who	leave	after	more	than	a	year	of	treatment.		
Patients	in	long-term	(i.e.	≥	1	year)	treatment	may	be	a	distinct	group	from	those	
only	retained	short-term.	For	example,	in	one	such	small	study	of	buprenorphine	
patients	in	treatment	for	over	2	years,	91%	of	urine	samples	had	no	evidence	of	illicit	
opioid	use22	suggesting	that	these	long-term	OBOT	patients	may	be	at	reduced	risk	for	
relapse	on	opiates,	although	still	at	risk	for	other	behaviors	such	as	diversion	of	
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buprenorphine.	Despite	the	possible	differences	between	long-term	patients	and	new	
patients,	the	guidelines	do	not	differ	in	their	recommendations	for	treating	or	
monitoring	patients	based	on	program	tenure.1,16	
Additionally,	the	number	patients	on	buprenorphine	is	large	and	rapidly	growing,	
with	over	32,000	patients	prescribed	buprenorphine	in	2011	from	only	2397	in	the	year	
2004.25	While	it	is	well	established	that	OUD	is	a	chronic	relapsing	disease26	requiring	
long-term	treatment1	and	a	substantial	proportion	of	patients	are	not	retained	in	
treatment	long-term,	a	significant	literature	exploring	long-term	retention	in	
buprenorphine	treatment	does	not	exist.	To	achieve	effective	large	scale	OBOT	with	
buprenorphine,	we	must	understand	long-term	treatment	retention,	and	risk	factors	for	
disengagement.	To	pursue	this	objective,	we	examined	a	large	cohort	of	patients	
treated	with	buprenorphine	over	a	twelve-year	period.		
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CONCEPTUAL	FRAMEWORK	
In	order	to	address	treatment	retention	in	this	challenging	patient	population	we	
borrowed	from	the	conceptual	framework	of	the	extensive	literature	on	treatment	
engagement	and	retention	for	patients	with	HIV.9,27–30	These	patient	populations	are	
similar	and	even	overlapping	in	many	ways,	as	they	represent	stigmatized	groups,	often	
with	complex	psycho-social	comorbidities,	whose	care	is	very	dependent	on	larger	
societal	structural,	social	and	cultural	factors,	and	require	long-term	treatment.		As	a	
basis	for	our	conceptual	framework	we	used	the	original	Social-Ecological	framework	
from	Roura	et	al.27	and	the	adapted	framework	by	MacPherson	et	al.31	(Figure	1)	
This	model	highlights	the	areas	we	will	explore	in	this	study.	We	will	
predominately	focus	on	Individual	Factors,	especially	the	patient’s	demographic	and	
medical	characteristics.	We	do	not	have	access	to	any	data	on	patient	beliefs	or	
attitudes	about	OUD	or	treatment,	although	these	traditionally	have	been	important	
factors	in	the	Social-Ecological	framework.	
Additionally	within	this	cohort	we	will	be	able	to	explore	some	Social-Cultural	
Factors	such	as	Networks,	specifically	education	level	and	race/ethnicity	and	Micro-
Economic	Factors,	specifically	employment.	Our	study	will	also	be	able	to	examine	the	
Structural	Factors	of	any	Policy	or	Economic	changes	over	the	12-year	study	period,	by	
controlling	for	year	of	enrollment,	as	well	as	the	impact	of	the	Legal	Environment,	
specifically	the	role	of	incarceration	in	interrupting	patient	treatment.	As	this	is	a	single	
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site	study	with	a	fairly	rigid	treatment	structure	across	patients	and	over	time,	we	will	
not	explore	Health	Facility	Factors,	and	thus	this	is	not	a	part	of	the	operational	
framework.	(Figure	2)	
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Figure	1:	Conceptual	Framework	of	Retention	in	OBOT	Care,	based	on	both	the	original	
Social-Ecological	framework	from	Roura	et	al.	(2009),	and	the	adapted	framework	by	
MacPherson	et	al.	(2012)	
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Figure	2:	Operational	Framework	of	Retention	in	OBOT	Care	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Individual Factors 
• Age 
• Gender 
• Other medical co-
morbidities (HIV, HCV, 
Psychiatric) 
•Prior treatment history 
(methadone, 
buprenorphine, detox) 
• History of heroin use 
(vs. opioid pills only) 
 
Year of enrollment  
(policy, legal or economic 
changes) 
Social and Cultural 
Factors 
• Socio-cultural 
environment (race) 
• Networks and 
dependencies 
(education, 
employment) 
• Micro-economic 
context (employment) 
Retention in OUD treatment in OBOT clinic 
		 11	
METHODS	
Design	Overview	
This	is	a	retrospective	cohort	study,	one	of	a	series	of	DROP	(Disenrollment	and	
Re-engagement	in	an	OBOT	Program)	projects	examining	patients	treated	with	
buprenorphine	at	the	OBOT	Program	at	Boston	Medical	Center	from	January	1,	2002	to	
February	28,	2014.	The	primary	aim	of	this	study	was	to	describe	patient	characteristics	
associated	with	OBOT	treatment	retention	for	at	least	one	year.	Additionally,	in	
exploratory	analyses,	we	described	reasons	for	disengagement	from	treatment	periods	
of	at	least	one	year	compared	to	those	of	less	than	one	year.	
Specific	Aims	and	Hypotheses	
	 The	primary	aim	of	this	study	was	to	describe	the	patients	who	at	any	point	
remain	in	OBOT	for	at	least	one	continuous	year	and	the	patient	characteristics	(e.g.	
age,	race,	psychiatric	comorbidities,	poly-substance	use	or	other	patient-specific	factors)	
associated	with	OBOT	treatment	retention	for	at	least	one	year.	An	exploratory	aim	was	
to	describe	the	reasons	for	disengagement.	We	hypothesized	that	the	patient-specific	
factors	associated	with	increased	likelihood	of	a	treatment	period	of	≥	1	year	would	be:	
older	age,	white	race/ethnicity,	lack	of	psychiatric	comorbidities	and	no	poly-substance	
use.	We	hypothesized	that	the	primary	reason	for	patient	disengagement	after	a	year	or	
more	of	treatment	is	due	to	a	monitored	taper	off	of	buprenorphine	in	the	setting	of	
ongoing	recovery,	and	not	due	to	addiction	relapse,	as	is	the	norm	for	shorter	treatment	
episodes.		
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Study	setting	
	 This	OBOT	program,	established	in	2002	at	Boston	Medical	Center,	a	large	urban	
safety-net	hospital,	uses	a	nurse	care	manager	as	central	to	its	collaborative	care	
model.4	It	has	been	disseminated	to	community	health	centers	and	is	known	as	the	
Massachusetts	Model.32,33	Patients	enrolled	in	the	OBOT	program	receive	integrated	
primary	care	and	buprenorphine	treatment	within	the	Primary	Care	Clinic.	Patients	are	
initially	typically	seen	a	minimum	of	weekly	by	a	nurse	care	manager	for	the	first	month	
and	every	three	months	by	their	buprenorphine	prescriber,	with	increased	or	decreased	
intervals	based	on	clinical	stability.	Weekly	substance	use	counseling	is	required	for	all	
patients.	The	majority	of	patients	receive	counseling	outside	of	Boston	Medical	Center,	
either	through	the	Boston	Public	Health	Commission’s	group	therapy	programs	or	
through	community	mental	health	providers.	Patients	in	the	OBOT	program	during	
some	of	the	study	period	did	have	enhanced	access	to	co-located	psychiatry	services,	
however	this	was	a	limited	resource,	and	the	majority	of	patients	received	psychiatric	
care	within	a	separate	Behavioral	Health	Clinic	or	from	community	providers.	However,	
the	location	of	patients’	counseling	services	and	their	use	of	behavioral	health	services	
was	not	consistently	documented	in	the	medical	record,	and	thus	these	variables	were	
not	available	for	the	purposes	of	this	study.	
Study	population	
This	study	included	all	patients	who	entered	treatment	in	the	OBOT	clinic	prior	
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to	February	28,	2013	in	order	to	allow	all	patients	to	have	at	least	1-year	follow-up	
available	for	examination.	This	clinic	serves	a	diverse	population	of	men	and	women,	
who	are	at	least	18	year	old.	This	clinic	does	not	include	pregnant	patients.	All	patients	
included	in	this	retrospective	cohort	study	completed	the	standard	clinical	intake	
process	and	successfully	completed	buprenorphine	induction.		
Data	sources	and	collection	
Data	were	initially	abstracted	from	the	Electronic	Medical	Record	(EMR)	at	
Boston	Medical	Center	with	the	assistance	of	the	hospital’s	Clinical	Data	Warehouse.34	
Data	included	basic	demographics,	medical	diagnoses	and	laboratory	tests.	When	data	
were	incomplete	or	lacked	sufficient	detail,	two	trained	reviewers	and	a	physician	
manually	reviewed	de-identified	clinic	notes.	Manual	chart	review	was	required	to	
obtain	more	complete	details	regarding	substance	use	history,	prior	OUD	treatment,	
and	reasons	for	disengaging	from	OBOT.		
Outcome	
Our	primary	outcome	of	interest	was	at	least	one	year	of	continuous	treatment	
with	buprenorphine	in	OBOT.	In	this	study	patients	were	allowed	to	have	multiple	
engagement	periods	with	the	OBOT	program.	The	start	of	the	treatment	period	was	the	
date	of	completion	of	buprenorphine	induction	as	documented	by	receipt	of	the	first	
buprenorphine	prescription.	Disengagement	occurred	when	the	patient	1)	had	no	active	
buprenorphine	prescription	for	60	days	and	2)	did	not	make	any	clinic	contact	for	60	
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consecutive	days.	If	disengagement	criteria	were	met,	the	date	of	disengagement	was	
designated	as	the	last	day	of	an	active	prescription	or	clinic	contact,	whichever	was	
later.	One	continuous	year	of	treatment	was	defined	as	a	period	in	which	the	individual	
was	in	treatment	for	at	least	365	days,	as	long	as	any	gap	in	care	was	less	than	60	days.	
A	new	treatment	period	began	with	a	new	buprenorphine	induction	prescription.	
Treatment	periods	of	at	least	one	continuous	year	were	designated	“	≥1	year	retention”	
periods	and	patients	who	ever	achieved	≥1	year	retention	were	designated	“OBOT	
veterans”.	We	also	performed	additional	exploratory	analyses	looking	at	factors	
associated	with	a	≥	2	year	treatment	period.	For	the	≥	2	year	treatment	period	analyses	
we	further	restricted	our	inclusion	criteria	to	only	include	patients	who	entered	
treatment	in	the	OBOT	clinic	prior	to	February	28,	2012	in	order	to	allow	all	patients	to	
have	at	least	2	year	follow-up	available	for	examination.	
Reason	for	disengagement	
After	the	disengagement	date	was	identified,	the	research	associates	and	
primary	investigator	reviewed	the	three	de-identified	clinic	notes	immediately	prior	to	
the	disengagement	date	and	the	three	de-identified	notes	immediately	after	the	
disengagement	date,	if	available.	These	notes	were	reviewed	to	elucidate	the	reason	
the	patient	had	ended	treatment.	For	each	treatment	period,	the	reasons	for	
disengagement	were	coded	into	at	least	one	of	the	eleven	possible	categories,	with	
multiple	reasons	allowed	for	a	single	treatment	period.		The	final	categories	were	
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refined	through	weekly	teams	meetings,	and	the	codebook	revised,	with	all	reasons	
coded	to	consensus.	Reasons	were	coded	based	on	content	analysis,	using	existing	
theory	from	prior	work,3,4,35	clinical	knowledge	of	the	research	team	and	reasons	listed	
for	termination	of	treatment	traditionally	reported	to	the	state	Department	of	Public	
Health’s	Bureau	of	Substance	Abuse	Services.36	The	final	eleven	categories	included:	1)	
Clinic	Problems	2)	Important	Life	Events	3)	Health	Contraindications	4)	Addiction	
Relapse	5)	Taper	Off	6)	Transfer	7)	Legal	Issues		8)	Insurance	or	Payment	Issues;	9)	
Death;	10)	Unknown	and	11)	Did	Not	Disengage		(Table	1).	
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Table	1.	Categories	of	Reasons	for	OBOT	Disengagement	
Reason	 Definition	
Clinic	Problems	 Administrative	discharge	for	non-compliance	with	clinic	
rules	or	conflict	in	the	patient-provider	relationship	
leading	patient	to	decide	to	leave	
Important	Life	Events	 Change	in	housing	(e.g.	moving,	homelessness)	or	
change	in	social	support	(e.g.	the	loss	of	loved	one)	
Health	Contraindications	 Medication	side	effect	from	buprenorphine	or	
significant	surgery	or	pain	for	which	discontinuation	of	
buprenorphine	was	indicated	
Addiction	Relapse	 Relapse	with	opioids	and/or	continued	use	of	other	illicit	
substances,	often	resulting	in	the	clinic	recommending	
transfer	to	methadone	or	detoxification	
Taper	Off	 Taper	off	of	buprenorphine;	including	both	self-taper	
and	a	prescribed	taper	from	clinic	staff	
Transfer	 Transfer	to	another	buprenorphine	or	naltrexone	clinic	
Legal	Issues	 Incarceration	or	concern	about	future	incarceration	
Insurance	or	Payment	
Issues	
Loss	of	insurance,	change	of	insurance	or	high	co-
payments	for	medications	or	visits	
Death	 Documentation	of	death	in	medical	record	
Unknown	 No	reliable	or	clear	documentation	of	a	reason	
Did	Not	Disengage	 	Patient	still	engaged	in	care	at	the	end	of	the	study	
period	
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Statistical	Analyses	
Descriptive	statistics	were	obtained	for	patient	demographics	and	clinical	
characteristics	using	proportions	for	categorical	variables,	and	median	(interquartile	
range)	for	continuous	variables.	Proportions	and	95%	confidence	intervals	were	
calculated	for	the	number	of	patients	with	the	outcome	of	interest	(≥1	year	of	
continuous	treatment)	and	the	proportion	of	patients	with	each	stated	reason	for	
leaving	treatment.		The	potential	predictors,	all	assessed	at	initial	enrollment,	included	
the	following:	age,	gender,	race/ethnicity	(white,	black,	Hispanic	and	other),	completion	
of	high	school	level	of	education,	employment,	Hepatitis	C	(HCV)	antibody	status,	
presence	of	psychiatric	diagnoses	on	the	problem	list,	history	of	heroin	use,	history	of	
prior	buprenorphine	treatment	and	current	use	of	any	cocaine	alcohol	or	illicit	
benzodiazepines	based	on	self-report	on	admission	to	the	clinic.	Descriptive	bivariate	
comparisons	of	patients	who	were	OBOT	veterans	(ever	achieved	≥	1	year	of	treatment)	
versus	those	who	were	not	were	conducted	in	preliminary	analyses	using	chi-square	
tests	and	Wilcoxon-tests.	
Unadjusted	and	adjusted	generalized	estimating	equations	(GEE)	logistic	
regression	models	were	used	to	analyze	the	binary	outcome	of		“one	year	or	more	
treatment	retention”	incorporating	observations	across	all	OBOT	treatment	periods.	As	
some	patients	contributed	more	than	one	treatment	period,	the	GEE	was	used	to	
account	for	the	correlation	due	to	the	repeated	measurements.		The	GEE	models	were	
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fit	using	an	independence	working	correlation	matrix	and	results	are	reported	using	the	
empirical	variance	estimator.		Factors	associated	with	≥1	year	OBOT	retention	for	any	
given	treatment	period	were	identified	using	generalized	estimating	equation	logistic	
regression	models	to	allow	a	single	patient	to	contribute	multiple	treatment	periods.	
Prior	to	regression	analyses,	Spearman	correlation	coefficients	were	calculated	between	
independent	variables	and	no	pair	of	variables	had	a	correlation	>0.40.		Potential	
predictors	that	were	significant	in	bivariate	analyses	(p<0.10)	were	then	included	in	a	
final	multivariable	model	along	with	the	potential	confounders	age	(known	from	the	
literature	to	be	associated	with	short-term	treatment	retention),	calendar	year,	and	the	
ordinal	number	of	the	given	treatment	period	(ranging	from	1st	to	≥4th).	Calendar	year	
(categorized	as:	2003-2007;	2008-2010;	2011-2014)	was	included	in	multivariable	
models	given	the	long	time	span	in	the	data	set,	to	account	for	possible	secular	trends	
and	changes	in	the	clinic.	All	available	data	was	included	in	the	repeated	measures	
analyses.	The	above	model	was	also	fit	for	the	exploratory	outcome	of	“two	years	or	
more	of	continuous	treatment”	for	any	given	engagement.		Due	to	the	exploratory	
nature	of	these	analyses,	no	adjustments	were	made	for	multiple	comparisons.	
The	reasons	for	disengagement	were	described	for	both	the	treatment	periods	
of	≥	1	year	and	those	less	than	a	year	and	compared	in	bivariate	analyses	accounting	for	
repeated	measures.	All	analyses	were	completed	using	SAS	9.3	software	(Cary,	NC).	The	
Boston	University	Institutional	Review	Board	approved	this	study.	
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RESULTS	
Sample	characteristics	
During	the	12-year	study	period,	1237	adult	patients	entered	the	OBOT	for	
buprenorphine	program.	The	majority	of	patients	were	male	(61.4%),	of	white	
race/ethnicity	(68.2%),	unemployed	(64.2%),	and	had	completed	high	school	or	a	more	
advanced	degree	(64.3%).	In	terms	of	medical	characteristics,	66.0%	had	any	psychiatric	
diagnosis,	58.7%	had	positive	Hepatitis	C	(HCV)	antibody	and	78.5%	were	smokers.	The	
median	buprenorphine	dose	was	16mg	per	day,	median	age	of	first	opioid	use	was	20	
years	and	age	of	first	OBOT	enrollment	was	37	years.		The	median	number	of	unique	
engagement	periods	with	OBOT	was	1	(minimum	1,	maximum	5)	and	the	median	length	
of	each	patient’s	longest	engagement	period	was	413	days	(Interquartile	Range	145,	
1189).		Of	the	1237	unique	adult	patients	who	entered	OBOT,	53.7%(664/1237)	ever	
remained	in	OBOT	at	any	point	for	a	continuous	year	or	more	and	were	classified	as	
“OBOT	veterans”.	Among	those	with	sufficient	follow-up	time,	40.6%	(469/1156)	of	
patients	ever	remained	in	OBOT	for	a	continuous	two	year	period	or	longer,	23.6%	
(155/652)	of	patients	for	5	years	or	more	and	5.2%	(3/58)	of	patients	for	a	continuous	
10	year	period.	(Table	2)	
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Table	2.	Bivariate	Analyses	of	Baseline	Characteristics	of	OBOT	Patients	over	Twelve-
Year	Study	Period	(N=	1237)	
Demographics	 Total	(N	=1237)	
N	(%)	or	median	
(IQR)	
Patients	With	a	
≥1	Year	
Retention	
(N=664)	
N	(%)	or	median	
(IQR)	
Patients	With	<1	
Year	Retention	
(N=573)	
N	(%)	or	median	
(IQR)	
p-value	
Age	at	Enrollment,	
years	(N	=1222)	
37	(28,	46)	 37	(28,	46)	 38	(28,	46)	 0.76	
Female	(N	=1222)	 472	(38.6%)	 295	(44.4%)	 177	(31.7%)	 <.0001	
Race/Ethnicity		
(N	=	1203)	
White	
Black	
Hispanic	 	
Other	
	
	
821	(68.2%)	
179	(14.9%)	
187	(15.5%)	
16	(1.3	%)	
	
	
486	(74.0%)	
75	(11.4%)	
86	(13.1%)	
10	(1.5%)	
	
	
335	(61.4%)	
104	(19.0%)	
101	(18.5%)	
6	(1.1%)	
	
<.0001	
High	school/GED	or	
Higher	(N	=	986)	
634	(64.3	%)	 391	(65.9%)	 243	(61.8%)	 0.50	
Unemployed		
(N	=	1177)	
752	(60.8%)	 389	(59.8%)	 363	(69.7%)	 <.0001	
Any	Psychiatric	
Diagnoses	(N	=	1224)	
808	(66.0%)	 482	(72.9%)	 326	(57.9%)	 <.0001	
HIV	Positive	(N	=	469)	 23	(4.9%)	 10	(3.7%)	 13	(6.5%)	 0.16	
HCV	Antibody	Positive	
(N	=	1084)	
636	(58.7%)	 306	(52.2%)	 330	(66.3%)	 <.0001	
Alcohol	Use	at	
Enrollment	(N	=1237)	
213	(17.2%)	 96	(14.5%)	 117	(20.4%)	 0.006	
Cocaine	Use	at	
Enrollment	(N	=	1237)	
164	(13.3%)	 67	(10.1%)	 97	(16.9%)	 0.0004	
Illicit	Benzodiazepine	
Use	at	Enrollment		
(N	=1237)	
108	(8.7	%)	 51	(7.7%)	 57	(9.9%)	 0.16	
Ever	heroin	use		
(N	=	1237)	
1063	(85.9%)	 547	(82.4%)	 516	(90.1%)	 0.0001	
Prior	Buprenorphine	
Treatment	(N	=	1237)	
404	(32.7%)	 241	(36.3%)	 163	(28.4%)	 0.003	
Age	at	first	Opioid	Use	
(N=1164)	
20	(17,	26)	 20	(17,	26)	 20	(16,	26)	 0.71	
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Primary	Outcome:	Treatment	Retention	≥	1	Year	
	
There	were	1605	total	OBOT	treatment	periods	among	the	1237	patients	in	this	
study,	as	each	patient	could	contribute	multiple	observations.	Almost	half,	45.7%	
(717/1605),	of	all	treatment	periods	resulted	in	retention	in	OBOT	with	buprenorphine	
for	a	continuous	year.	In	adjusted	GEE	analyses	using	1345	complete	observations,	
female	gender	(Adjusted	Odds	Ratio	[AOR]	1.55,	95%	CI	[1.20,	2.00])	psychiatric	
diagnosis	(AOR	1.75	[1.35,	2.27])	and	older	age	(AOR	1.19	per	10	year	increase	[1.05,	
1.34])	were	associated	with	greater	odds	of	≥1	year	retention.	Unemployment	(AOR	
0.72	[0.56,	0.92]),	HCV	positive	(AOR	0.59	[0.45,	0.76]),	black	race/ethnicity	(AOR	0.53	
[0.36,	0.78])	and	Hispanic	race/ethnicity	(AOR	0.66	[0.48,	0.92]),	compared	to	white,	
were	associated	with	lower	odds	of	≥1	year	retention.	Any	alcohol	(AOR	0.91	[0.65,	
1.25])	and	cocaine	(AOR	0.85	[0.61,	1.19])	use	did	not	appear	to	be	associated	with	
retention.		In	terms	of	the	covariates	in	the	model,	treatment	periods	starting	in	the	
year	2011	or	later	(AOR	0.62	[0.42,	0.90])	and	treatment	periods	that	were	the	patient’s	
second	(AOR	0.39	[0.28,	0.53])	or	third		(AOR	0.34	[0.18,	0.64])	with	OBOT	were	less	
likely	to	be	greater	than	one	year.	(Table	3)	
Retention	for	≥	2	Years	
In	adjusted	GEE	analyses,	female	gender	(AOR	1.44		[1.09,	1.91])	and	psychiatric	
diagnoses	(AOR	1.97	[1.48,	2.62]),	and	older	age	(AOR	1.27	per	10	year	increase	[1.11,	
1.45])	had	increased	odds	of	having	the	treatment	period	lasting	≥	2	years.		Factors	
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associated	with	decreased	odds	of	any	given	treatment	period	lasting	≥	2	years	
included:	unemployment	(AOR	0.69		[0.53,	0.91]),	HCV	positive	(AOR	0.56		[0.42,	0.75])	
and	Hispanic	race/ethnicity	(AOR	0.64		[0.43,	0.94]).	The	results	for	the	covariate	“year	
of	enrollment”	were	not	significant	and	for	the	covariate	“number	of	prior	treatment	
periods”,	only	1	prior	OBOT	stint	was	significantly	associated	with	decreased	odds	of	≥	2	
years	retention.	(Table	3)	
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Table	3.	Adjusted	Odds	Ratios	for	≥1	Year	Treatment	Retention	and	≥	2	Years	Treatment	
Retention	as	compared	to	<1	Year	
Independent	
Variables	
Primary	Outcome:	
≥1	year	retention	
Unadjusted	OR	(95%	
CI)	
Primary	Outcome:	
≥1	year	retention	
Adjusted	OR	(95%	
CI)	b	
Exploratory	
Outcome:	
≥2	years	retention	
Adjusted	OR	(95%	
CI)c	
Age	at	Enrollmenta	 0.99		(0.89,	1.09)	 1.19		(1.05,	1.34)*	 1.27		(1.11,	1.45)*	
Gender	
	 Male	
	 Female	
	
Reference	
1.62		(1.31,	2.01)*	
	
Reference	
1.55		(1.20,	2.00)*	
	
Reference	
1.44		(1.09,	1.91)*	
Race/Ethnicity	
	 White	
	 Black	
	 Hispanic	
												Other	
	
Reference	
0.52		(0.38,	0.71)*	
0.56		(0.42,	0.74)*	
1.59		(0.62,	4.05)	
	
Reference	
0.53		(0.36,	0.78)*		
0.66		(0.48,	0.92)*	
2.03		(0.57,	7.17)	
	
Reference	
0.70		(0.46,	1.08)	
0.64		(0.43,	0.94)*	
0.91		(0.23,	3.59)	
Unemployment	 0.65		(0.52,	0.81)*	 0.72		(0.56,	0.92)*	 0.69		(0.53,	0.91)*	
Highschool/GED	or	
Higher	
1.09		(0.86,	1.39)	 ^^^^	 ^^^	
Any	Psychiatric	
Diagnoses	
1.68		(1.35,	2.08)*	 1.75		(1.35,	2.27)*	 1.97		(1.48,	2.62)*	
Prior	
Buprenorphine	
Treatment	
1.42		(1.13,	1.77)*	 1.14		(0.88,	1.48)	 1.29		(0.96,	1.72)	
History	of	Ever	
Heroin	Use	
0.57		(0.41,	0.78)*	 0.90		(0.61,	1.32)	 0.72		(0.48,	1.09)	
Alcohol	Use	at	
Enrollment	
0.78		(0.59,	1.04)	 0.88		(0.63,	1.23)	 0.76		(0.53,	1.11)	
Cocaine	Use	at	
Enrollment	
0.60		(0.44,	0.80)*	 0.86		(0.61,	1.22)	 0.79		(0.53,	1.17)	
Benzodiazepine	
Use	(Illicit)	at	
Enrollment	
0.90		(0.63,	1.29)	 ^^^^	 ^^^^	
Hepatitis	C	
Antibody	Positive	
0.55		(0.44,	0.68)*	 0.59		(0.45,	0.76)*	 0.61		(0.47,	0.80)*	
Calendar	Year	
2003–2007	
2008–2010	
2011–2014	
	
Reference	
1.07		(0.86,	1.34)	
0.91		(0.66,	1.27)	
	
Reference	
0.91		(0.70,	1.18)	
0.62		(0.42,	0.90)*	
	
Reference	
0.98		(0.74,	1.31)	
0.89		(0.55,	1.45)	
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Number	OBOT	
Period	
1st	(N=958)	
2nd	(N=	209)	
3rd	(N=54)	
≥4th	(N=16)	
	
Reference	
0.45	(0.34,	0.59)*	
0.39	(0.22,	0.66)*	
0.48	(0.18,	1.25)	
	
Reference	
0.39		(0.28,	0.53)*	
0.34		(0.18,	0.64)*	
0.45		(0.16,	1.32)	
	
Reference	
0.52		(0.35,	0.76)*	
0.78		(0.37,	1.65)	
0.41	(0.04,	3.96)	
	
Legend:	aAge	OR	represents	odds	for	every	10-year	increase	in	age;	b	Primary	outcome	
of	≥1	year	retention	uses	an	N	of	1345	observations;	b	Exploratory	outcome	of	≥2	year	
retention	uses	an	N	of	1186	observations;	History	of	Heroin-	reported	use	of	heroin,	
with	or	without	opioid	pills,	as	compared	to	use	of	opioid	pills	only;	Prior	Buprenorphine	
Treatment	–	patient	self-report	of	prior	buprenorphine	treatment	with	any	
buprenorphine	provider;	Number	OBOT	Period–	patient’s	ordinal	number	treatment	
period	in	the	OBOT	program	^^	not	included	in	final	model	
*	p-value	<	0.05	
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Reasons	for	disengagement	
The	most	common	reason	for	disengagement	among	all	treatment	periods	was	
Relapse	(32.6%).	Relapse	appeared	to	be	a	less	common	reason	for	disengagement	for	
the	of	treatment	periods	of	≥	1	year	(23.3%)	compared	to	those	of	<1	year	periods	
(40.1%).	The	≥	1	year	treatment	periods	appeared	less	likely	to	end	due	to	be	Legal	
Issues	(2.8%	vs.	4.7%)	or	Clinic	Problems	(7.3%	vs.	11.7%).	No	disengagement	due	to	
Death	was	recorded	in	the	medical	record.		(Table	4)	
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Table	4:	Reasons	for	disengagement	from	OBOT	for	All	Treatment	Periods,	Treatment	
Periods	≥1	year	and	<1	year	
Reason		 All		
(N=1605)	
N	(%)	
≥1	year-long		
(N=717)	
N	(%)	
<	1	year	
(N=888)	
N	(%)	
Clinic	Problems	 156	(9.7%)	 52	(7.3%)	 104	(11.7%)	
Important	Life	
Events			
68	(4.2%)	 28	(3.9%)	 40	(4.5%)	
Health	
Contraindications	
45	(2.8%)	 15	(2.1%)	 30	(3.4%)	
Relapse	 523	(32.6%)	 167	(23.3%)	 356	(40.1%)	
Taper	 53	(3.3%)	 33	(4.6%)	 20	(2.3%)	
Legal	Issues	 62	(3.9%)	 20	(2.8%)	 42	(4.7%)	
Transfer	 86	(5.4%)	 40	(5.6%)	 46	(5.2%)	
Insurance	issues	 7	(0.4%)	 6	(0.8%)	 1	(0.1%)	
Death	 0	(0%)	 0	(0%)	 0	(0%)	
Unknown	 492	(30.6%)	 162	(22.6%)	 330	(37.2%)	
Censor	 298	(18.6%)	 260	(36.3%)	 38	(4.3%)	
	
Legend:	1)	Clinic	Problems	(e.g.	administrative	discharge	for	non-compliance	clinic	rules	
or	conflict	in	the	patient-provider	relationship);	2)	Important	Life	Events		(including	
change	in	housing,	change	in	social	support	such	as	the	loss	of	loved	one);	3)	Health	
Contraindications	(including	medication	side	effects,	significant	surgery	or	pain);	4)	
Addiction	Relapse	(with	opioids	or	continued	use	of	other	illicit	substances,	often	
resulting	in	the	clinic	recommending	transfer	to	methadone	or	detoxification);	5)	Taper	
Off;	6)	Transfer	(to	another	buprenorphine	or	naltrexone	clinic);		7)		Legal	Issues		
(including	incarceration	and	concern	about	future	incarceration);		8)	Insurance	or	
Payment	Issues;	9)	Death;	10)	Unknown	(no	reliable	or	clear	documentation	of	a	reason)	
and	11)	Censor	(still	engaged	in	care	at	the	end	of	the	study	period)	
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DISCUSSION	
In	this	12-year	study	of	patients	on	buprenorphine	in	a	single	well-established	
OBOT	program,	over	half	of	the	patients	remained	in	treatment	for	at	least	one	
continuous	year.	Achieving	OBOT	veteran	status	is	important	as	accumulating	evidence	
finds	that	significant	benefits	are	associated	with	remaining	on	buprenorphine	for	at	
least	one	year,	more	than	simply	decreased	opioid	use;37	these	include	decreased	
hospitalizations	and	emergency	department	visits.38	Additionally,	there	is	evidence	that	
participating	in	primary	care	clinic	integrated	with	OUD	treatment	can	improve	patients’	
overall	well-being	and	quality	of	life.39	Patients	in	recovery	from	heroin	use	for	at	least	
one	year	also	report	improved	quality	of	life.40	Given	this	myriad	of	benefits,	it	is	
extremely	important	that	we	as	providers	better	understand	how	to	retain	patients	in	
care	long-term.	My	main	motivation	for	researching	this	topic	was	to	help	myself,	and	
other	providers,	improve	the	health	and	wellbeing	of	our	patients.	
	 Prior	work	has	found	that	female	patients	are	less	likely	to	engage	in	substance	
use	treatment	and	also	face	unique	barriers	to	entry,	including	lack	of	childcare,	
concerns	about	losing	custody	of	their	children	and	difficulty	accessing	care	while	
pregnant.41,42	Despite	these	barriers,	in	this	study,	female	patients	had	increased	long-
term	treatment	retention.	Perhaps	because	women	must	already	overcome	these	
significant	barriers	to	care,	those	who	do	make	it	into	care	are	highly	engaged.	
Additionally	pregnancy	and	children	in	general	may	be	a	strong	motivator	for	women	to	
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seek	and	remain	in	care.43		My	clinical	experience	parallels	what	others	have	suggested,	
that	female	patients	may	both	gain	more	benefit	from	and	more	easily	accommodate	to	
the	structure	of	a	substance	use	clinic44.	Overall	female	patients	are	less	oppositional	
and	more	compliant	with	the	treatment	structure,	which	may	be	protective	from	some	
of	the	Clinic	Reasons	for	treatment	disengagement.	This	finding	about	female	advantage	
for	OBOT	>1	year	retention	is	consistent	with	others’	work	on	short-term	treatment	
retention.44,45	While	it	is	heartening	that	female	patients	are	well	retained	in	OBOT,	
there	remains	much	to	be	done	to	overcome	the	particular	stigma	and	barriers	for	
women	to	get	into	care	in	the	first	place.	These	possible	interventions	could	include	
additional	social	work	support	with	particular	focus	on	maintaining	custody	of	children	
and	obtaining	low	cost	childcare.	
As	in	previous	studies,	increased	age	was	associated	with	longer	treatment	
engagement.3,15	Although	this	may	seem	counter-intuitive	to	an	outsider,	as	younger	
patients	likely	have	shorter	course	of	disease,	and	thus	may	be	milder	and	easier	to	
treat,	much	prior	research	and	my	own	clinical	experience	support	that	in	fact	older	
patients	have	improved	treatment	retention	and	outcomes.	Although	I	do	not	believe	in	
any	way	that	patients	need	to	reach	“rock	bottom”	before	engaging	in	treatment46,	in	
my	experience	patients	who	have	experienced	more	serious	consequences	of	their	
disease	are	more	highly	motivated.	Younger	patients	may	have	not	yet	had	severe	life	
consequences	related	to	their	OUD	and	thus	may	be	more	ambivalent	about	treatment.	
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	Also	consistent	with	previous	work,	being	employed,21,47	likely	a	marker	of	
socioeconomic	stability,	was	associated	with	treatment	retention.	Additionally	
employment	may	be	a	factor	that	is	protective	against	a	common	anecdotal	reason	for	
relapse	or	use:	boredom.	Future	interventions	to	assist	with	treatment	retention	may	
include	employment	assistance	to	help	patients	engage	in	work	in	an	effort	to	maintain	
recovery.	
Unlike	prior	work,	we	did	not	detect	a	significant	relationship	between	
polysubstance	use	at	enrollment	(alcohol,	cocaine	or	illicit	benzodiazepine)	and	long-
term	treatment	retention.3,19,21,22	While	polysubstance	use	may	significantly	impact	
short-term	retention,	this	may	be	less	of	an	influence	for	stable	patients	who	have	been	
in	treatment	for	a	longer	period	of	time.	However,	even	among	the	OBOT	veterans,	
almost	one	quarter	(23.3%)	ended	with	relapse,	highlighting	the	importance	of	
appreciating	the	OUD	as	a	chronic	disease	when	approaching	its	treatment	26.		
Black	and	Hispanic	race/ethnicity	were	each	associated	with	poorer	treatment	
retention	in	this	study	compared	to	whites,	consistent	with	past	findings	that	minorities	
are	less	likely	to	engage	in	substance	use	care48	and	less	likely	to	be	retained	in	
substance	use	treatment47,	including	buprenorphine	treatment.15	We	did	an	exploratory	
analysis	to	see	whether	non-white	patients	were	disproportionately	affected	by	Legal	
Issues	given	the	increased	frequency	of	incarceration	of	minority	in	the	United	States	of	
if	minorities	were	disproportionately	affected	by	Clinic	Issues,	demonstrating	that	there	
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was	some	systematic	bias	in	clinic	rule	enforcement	for	minority	patients.	We	did	not	
detect	significant	differences	in	the	frequency	for	either	of	these	reasons,	or	any	other	
reason	for	disengagement	for	minorities	as	compared	to	Whites.		Understanding	and	
addressing	this	disparity	in	outcomes	for	minority	patients	who	are	affected	by	the	
opioid	epidemic,	needs	to	become	an	addiction	treatment	priority.	
Additionally,	our	finding	of	increased	odds	of	≥1	year	treatment	retention	for	
patients	with	a	psychiatric	diagnosis	warrants	additional	exploration.	No	specific	
psychiatric	diagnosis	appeared	to	be	driving	this	relationship.	Traditionally	it	has	been	
viewed	that	psychiatric	co-morbidities,	especially	those	that	are	poorly	controlled,	lead	
to	worse	opioid	use	disorder	treatment	outcomes.1,49–51		However,	some	newer	work,	
focused	specifically	on	response	to	buprenorphine,	has	begun	to	challenge	this	idea.	
Research	on	12-week	buprenorphine	treatment	outcomes	has	show	associations	
between	lifetime	diagnosis	of	depression	and	decreased	opioid	use52	and	the	presence	
of		a	co-occurring	psychiatric	diagnosis	was	associated	with		a	significantly	increased	
odds	of	achieving	abstinence,	independent	of	receiving	treatment	for	the	psychiatric	
condition.53	In	a	longer	term	study,	more	severe	depressive	symptoms	at	baseline	were	
associated	with	continued	opioid	agonist	therapy	enrollment	at	42	weeks2;	however,	
some	of	these	studies	were	done	in	patients	who	primarily	use	opioid	pills,	which	is	a	
not	the	profile	of		patients	included	in	this	study.		
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Buprenorphine	may	have	some	antidepressant	properties	which	could	explain	
this	relationship	between	depression	specifically	and	improved	buprenorphine	
treatment	outcomes	52,54.	Additionally	patients	with	more	severe	psychiatric	co-
morbidities	may	be	more	highly	motivated	to	obtain	medical	treatment	in	general	and	
benefit	more	from	the	structure	and	support	of	the	OBOT	setting53,55,56	even	
independent	of	receiving	specific	psychiatric	care57.	One	study	found	that	among	
patients	with	depression	and	substance	use	disorder,	simply	the	referral	to	substance	
use	treatment	significantly	improved	depression	symptoms.58	Additionally,	as	patients	
are	seen	monthly	in	OBOT,	there	is	an	opportunity	to	identify	psychiatric	comorbidities	
and	link	patients	to	psychiatric	care,	as	well	as	in	the	setting	at	Boston	Medical	Center,	
for	some	enhanced	access	to	co-located	psychiatry	services.	However,	our	findings,	
which	aggregate	the	presence	of	any	psychiatric	diagnosis	on	the	problem	list	and	are	
retrospective	in	nature	are	inadequate	to	fully	evaluate	this	relationship.	To	truly	
evaluate	the	relationship	between	psychiatric	co-morbidities	and	long-term	
buprenorphine	treatment	outcomes,	likely	a	prospective	future	study	would	be	
required.	This	study	would	need	to	include	formal	psychiatric	diagnostic	interviews	
repeated	over	time	to	assess	for	changes	in	disease	severity,	as	well	as	tracking	of	
medication	use.		
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Although	the	presence	of	psychiatric	comorbidities	was	associated	with	
increased	odds	of	long-term	treatment	retention,	this	finding	was	not	generalizable	to	
all	medical	comorbidities.	In	this	study	patients	who	were	HCV	antibody	positive	were	
less	likely	to	be	retained	for	year	or	more.	This	is	consistent	with	the	findings	of	a	study	
on	short-term	buprenorphine	treatment,	showing	that	HCV	antibody	positive	patients	
were	less	likely	to	be	opiate	abstinent59.	This	is	unfortunate,	as	testing	for	and	treating	
HCV	has	many	benefits	in	patients	with	OUD	and	has	been	successfully	integrated	in	
opioid	agonist	treatment	settings	60.	Opioid	agonist	treatment	is	associated	with	
improved	completion	of	anti-viral	treatment	for	hepatitis	C	61	and	patients	with	OUD	
and	HCV	have	reported	psychological	benefits,	including	decreased	internalized	stigma,	
upon	completion	of	HCV	treatment	62.		However	few	patients	have	their	hepatitis	C	
treated	63,	thus	being	HCV	antibody	positive,	especially	prior	to	the	widespread	
availability	of	interferon-free	regimens,	perhaps	does	not	create	an	additional	incentive	
to	engage	in	care,	and	instead	is	simply	a	marker	of	co-morbidity	and	high	risk	behaviors	
such	as	intravenous	drug	use	associated	with	more	severe	disease	and	instability.	I	
believe	it	is	possible	that	if	this	same	study	were	repeated	in	the	current	environment	of	
more	widespread	well	tolerated	treatment	for	HCV,	that	HCV	would	no	longer	be	
associated	with	decreased	odds	of	long-term	retention,	as	some	patients	would	be	
motivated	to	engage	in	care	in	order	to	complete	their	HCV	treatments.	
In	this	study	patient	use	of	buprenorphine	prior	to	OBOT	was	not	associated	with	
increased	odds	of	a	year-long	retention,	which	is	in	contrast	to	some	prior	work.4,20	
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Patients	were	most	likely	to	have	a	treatment	periods	of		≥	1	year	on	their	first	
treatment	period,	likely	signaling	that	patients	who	struggled	to	remain	in	OBOT	on	
their	first	attempt	continued	to	struggle	on	subsequent	enrollments.		
To	better	understand	patients’	treatment	trajectory	we	attempted	to	capture	
the	reasons	for	disengagement,	which	is	challenging	in	a	retrospective	chart	review.	It	
was	notable	that	relapse	appeared	to	be	a	less	common	reason	for	disengagement	
among	≥	1	year	treatment	periods	compared	to	those	shorter	periods.	This	is	important,	
as	a	large	focus	on	the	behavioral	counseling	that	is	part	of	OBOT	is	relapse	prevention.	
This	result	signals	that	we	may	be	appropriately	directing	our	resources	towards	an	
important	issue	for	these	patients.	However,	as	OUD	is	a	chronic	relapsing	disease	by	
definition	and	not	all	patients	benefit	equally	from	buprenorphine,	we	likely	cannot	ever	
achieve	a	0%	relapse	rate,	even	among	the	veteran	OBOT	patients.	Similar	to	previous	
studies	approximately	a	third	(30.6%)	of	treatment	periods	ended	for	unknown	
reasons.15,22.Unfortunately	given	the	lack	on	integration	of	the	larger	medical	system	we	
were	unable	to	know	what	happened	to	patients	who	stopped	communicating	with	the	
clinic.	The	Bureau	of	Substance	Abuse	Services	and	other	government	agencies	could	do	
more	to	track	and	monitor	patients	seeking	OUD	treatment	and	communicate	with	the	
patients’	provider	teams.		Not	surprisingly,	disengagement	due	to	Health	Issues	and	
Clinic	Issues	were	more	likely	to	be	in	shorter	engagements.	While	Health	Issues	may	be	
difficult	to	avoid,	it	is	important	to	examine	Clinic	Issues,	and	whether	we	are	creating	
undue	barriers	to	care	entry	or	retention.	
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Notably,	no	patients	disengaged	due	to	Death	in	this	study.	While	we	were	
unable	to	confirm	this	with	national	death	index	or	other	data	sources	this	is	consistent	
with	previous	research	demonstrating	the	mortality	benefit	of	buprenorphine.64–66	
Given	that	this	is	a	literal	life-saving	treatment,	it	is	essential	that	we	address	all	of	the	
disparities	in	treatment	retention	found	in	this	study.	
With	our	reasons	for	disengagement	data,	although	we	were	not	able	to	directly	
measure	some	our	Conceptual	Framework	Structural	measures	such	as	the	Legal	
Environment,	we	were	able	to	look	at	the	frequency	of	patients	reporting	the	reason	for	
leaving	treatment	as	Legal	Issues	(including	incarceration	and	fear	of	incarceration).	
Only	3.9%	(62/1605)	of	all	of	the	treatment	periods	ended	due	to	Legal	Issues.	However,	
there	has	been	important	work	recently	about	how	lack	of	continuation	of	MAT	in	jail	
and	prison	limits	patients	interest	in	re-engaging	in	post-incarceration	MAT67	and	in	
Massachusetts	only	pregnant	women	are	continued	on	MAT	while	incarcerated.	While	
the	numbers	of	patients	leaving	treatment	due	to	legal	issues	is	low,	these	patients	are	
at	high	risk	for	overdose	post-release68–70,	and	for	not	returning	to	care	after,	as	
illustrated	in	the	Rich	et	al.	paper67.	To	address	these	important	issues,	one	possible	
future	intervention	could	include	a	medical-legal	partnership	within	OBOT	clinic.	In	
addition,	further	political	advocacy	for	our	patients	to	allow	access	to	MAT	in	jail	and	
prison	is	an	important	cause	for	those	interested	in	improving	uptake	of	evidence-based	
addiction	treatment.	
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In	terms	of	exploring	the	impact	of	policy	issues,	while	in	this	study	we	were	not	
able	to	directly	measure	the	Conceptual	Framework	Structural	measure	of	the	Economic	
Environment	(e.g.	coverage	of	treatment	services),	we	were	able	to	look	at	the	
frequency	of	patients	reporting	the	reason	for	leaving	treatment	as	Insurance	Issues	and	
only	0.4%	(7/1605)	of	all	of	the	treatment	periods	ended	due	to	Insurance	Issues.	There	
may	be	under-reporting	of	these	reasons	in	this	study,	especially	given	the	high	
frequency	of	Unknown	reasons	when	patients	abruptly	leave	treatment;	however,	this	
data	is	suggestive	that	overall	the	Structural	Factors	in	the	Boston	area	are	conducive	to	
treatment	retention.	Notably	during	most	of	this	study	period	Massachusetts	had	
implemented	almost	universal	health	care	access.	It	would	be	of	interest	to	compare	
these	outcomes	to	a	treatment	clinic	in	another	state	where	there	may	be	more	
structural	barriers	to	care.	
Additionally,	as	noted	in	the	discussion	of	the	Conceptual	Framework,	this	study	
was	limited	as	we	did	not	have	access	to	any	data	on	the	Individual	Factor	“Personal	
beliefs	about	OUD,	and	treatment”,	although	these	traditionally	have	been	important	
factors	in	the	Social-Ecological	framework.	It	is	well	established	that	the	stigma	of	the	
disease	of	opioid	use	disorder	(OUD)	itself	as	well	as	the	stigma	surrounding	the	
medications	for	OUD	(methadone	and	buprenorphine)	are	both	barriers	to	entering	and	
remaining	in	long-term	evidence-based	OUD	treatment71–73.	Neither	did	we	have	access	
to	information	about	the	Socio-cultural	Environment	(e.g.	social	stigma	towards	drug	
use),	which	again	may	have	greatly	impacted	patient’s	treatment	retention.	Many	
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known	barriers	to	OUD	care	were	not	able	to	be	measured	in	this	study	including:	lack	
of	patient	and	provider	awareness	of	evidence-based	treatment	options,	lack	of	care	
integration	into	mainstream	medicine,	and	societal	stigma,	as	well	as	geographic	and	
financial	barriers.39,72,74–76	
Strengths	and	Limitations	
This	study	has	several	limitations.		It	is	a	single	site	retrospective	study	which	has	
potential	to	limit	generalizability	although	it	is	a	leading	model	of	buprenorphine	OBOT	
delivery.		Not	all	variables,	especially	reasons	for	disengagement,	could	be	accurately	
and	completely	captured.		We	were	unable	to	verify	death	or	incarceration	data	with	
additional	independent	data	sources.	Many	important	socio-ecological	predictors	of	
treatment	retention	were	unavailable	to	us,	including	patient	attitudes	and	belief,	as	
well	as	their	housing	status,	likely	both	important	predictors.		Nonetheless,	the	large	
number	of	patients,	long	follow-up	time	and	wide	range	of	variables	offers	a	unique	
perspective	on	long-term	buprenorphine	treatment	outcomes.	
CONCLUSIONS	AND	IMPLICATIONS	
Over	half	of	all	patient	initiating	buprenorphine	to	address	an	opioid	use	
disorder	were	able	to	establish	and	maintain	long-term	(≥	1	year)	treatment	in	Office	
Based	Opioid	Treatment	(OBOT).		However	non-white	race/ethnicity,	younger	age,	
hepatitis	C	antibody	positive	status	and	lack	of	employment	were	all	associated	with	
decreased	odds	of	long-term	retention.	Additional	research	and	interventions	are	
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needed	to	increase	long-term	engagement	in	this	lifesaving	treatment.	Possible	future	
interventions	including	ensuring	culturally	sensitive	care,	identifying	and	treating	
hepatitis	C	and	psychiatric	comorbidities	as	well	as	employment	assistance	to	facilitate	
long-term	continuous	care	for	all	patients.	Additionally,	further	work	is	needed	to	
explore	some	of	the	aspects	of	the	Social-Ecological	framework	that	were	not	able	to	be	
captured	in	this	study,	especially	patient	and	societal	attitudes	about	OUD	and	its	
treatment.	
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friend	or	foe?”	and	“Evidence	for	urine	drug	testing	
and	pain	contracts	in	primary	care”	
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5/2014–	Present	 Faculty	-	Chief	Resident	Immersion	Training	(CRIT)	 	
• Co-lead	workshops	on	SBIRT	and	motivational	
interviewing	as	part	of	a	four-day	immersion	training	
for	incoming	chief	residents	on	state-of-the-art	
methods	to	diagnose,	manage,	and	teach	about	
addiction	medicine	
	
7/2014–Present	 SBIRT	Training		
• Trainer	for	the	Massachusetts	SBIRT-TTA	(Screening	
Brief	Intervention	and	Referral	to	Treatment-	
Training	and	Technical	Assistance),	leading	
workshops	for	health	care	and	school	professionals	
at	sites	throughout	Massachusetts	on	screening	and	
evaluating	substance	use	disorders	
	 	
7/2014–Present	 Addiction	Consult	Service	Attending	Physician	
• With	faculty	and	residents,	developed	a	formal	
curriculum	for	this	new	consult	service		
• Teach	addiction	medicine	to	residents	rotating	on	
service	
• Mentor	MPH	students	on	quality	improvement	
evaluation	of	the	service	
	
10/2014–Present	 Addiction	Curriculum	for	Primary	Care	Residents	
• Develop	and	co-lead	a	three-day	immersion	
Addiction	Medicine	curriculum	for	Primary	Care	
Residents	
• Precept	residents	during	clinical	electives	in	
buprenorphine,	methadone	and	primary	care	clinics	
	
7/2015–Present	 Medical	Student	Research	Project	Mentor	
• Mentor	two	first-year	medical	students	on	summer	
research	projects,	including	data	collection,	
manuscript	preparation	and	supervising	clinical	
rotations	in	addiction	treatment	settings	
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Professional	Societies:		
	6/2011–Present			 Massachusetts	Medical	Society	 	 	 	
	 	
	3/2013–	Present	 Society	of	General	Internal	Medicine	
	11/2013–Present		 American	College	of	Physicians		
	5/2014–Present	 American	Society	of	Addiction	Medicine	
	11/2014–Present	 Association	for	Medical	Education	and	Research	in	
Substance	Abuse	
	3/2015–	Present	 College	on	Problems	of	Drug	Dependence	
	 	 	 	 	 	
Community	Activities:	
9/2015–	Present	 Member,	Committee	of	Interns	and	Residents	Opioid	
Working	Group	
• Collaborating	with	residents	on	advocacy	to	
politicians	and	government	officials	about	the	
trainee	perspective	on	the	opioid	epidemic	
	
9/2011–6/2014	 Co-coordinator,	Primary	Care	Program	Community	Service	
Project	
• Organizing	residents	and	allied	health	professionals	
to	participate	in	activities	with	local	Boston	
minority	youth	interested	in	health	careers	
	
9/2011–6/2014	 Chapter	Co-president	and	delegate,	Committee	of	Interns	
and	Residents		
• Leader	on	the	Contract	Bargaining	Committee,	
Patient	Care	Fund	Committee,	Health	Justice	
Committee,	and	representative	at	the	annual	
national	conference	for	the	residents’	union	
	
1/2012–1/2014	 	 Residency	Class	Representative	
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Other	support:	
Current:	
	 6/2014–6/2016	 CREST:	1UL1TR001430	from	the	National	Center	For	Advancing	
Translational	Sciences		
	 	 Role:	Fellow	
	 	
	 6/2015–6/2016	 BU-	CHART:	T32AI52074-10	from	the	National	Institute	of	Allergy	
and	Infectious	Diseases	
	 	 Role:	Fellow	
Past:	
	 6/2014–6/2015		 Next	Generation	Award	–	American	Board	of	Addiction	Medicine,	
total	$25,000	
	 	 Role:	Recipient				
	 6/2014–6/2015		 CARE	Unit	Training	Grant	R25DA013582-14	from	the	National	
Institute	on	Drug	Abuse	
	 	 Role:	Fellow			
	
Invited	Lectures	and	Conference	Presentations:	
Hui,	D;	Weinstein,	ZM;	Cheng,	DM;	Quinn,	E;	Labelle,C	and	Samet,	J.	Early	
Disengagement	and	Subsequent	Re-engagement	in	Office	Based	Opioid	Treatment	
(OBOT)	with	Buprenorphine	in	a	Large	Urban	Hospital.		
The	Society	of	General	Internal	Medicine	Northeast	Regional	Conference	–New	Haven,	
CT	3/2016		
The	Society	of	General	Internal	Medicine	National	Conference	–Hollywood,	FL	5/2016	
	
Roy	P;	Weinstein	ZM;	Yuh	D;	Neville	L	and	Walley	AY/	A	Curriculum	to	Improve	Resident	
Knowledge	and	Satisfaction	in	caring	for	Hospitalized	Patients	with	Addiction.		
The	Society	of	General	Internal	Medicine	Northeast	Regional	Conference	–New	Haven,	
CT	3/2016	
	 	 	 	 	 	 	 	
Weinstein,	ZM;	Cheng,	DM;	Quinn,	E;	Gryczynski,	G;	Labelle,C	and	Samet,	J.	
Psychopharmacotherapy	for	Patients	in	Primary	Care	Office	Based	Opioid	Treatment	
(OBOT)	with	Buprenorphine.		
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The	Association	for	Medical	Education	and	Research	in	Substance	Abuse	Conference	–	
Washington	D.C.,	11/2015	
	
Weinstein,	ZM.	From	student	to	teacher:	a	journey	in	adolescent	SBIRT.		
American	Society	of	Addiction	Medicine	Annual	Retreat	–	Chicago,	IL,	3/2015	
	
Abstract	Poster	Presentations:		
Weinstein,	ZM;	Cheng,	DM;	Quinn,	E;		Hui,	D;	Kim,	B;	Gryczynski,	G;	Labelle,C	and	
Samet,	J.	The	Impact	of	Psychopharmacotherapy	on	Disenrollment	from	Office	Based	
Opioid	Treatment	(OBOT)	with	Buprenorphine.		
College	on	Problems	of	Drug	Dependence	Conference	–Palm	Springs,	CA,	6/2016	
	
Trowbridge,	P;	Weinstein,	Z;	Kerensky,	T;	Roy,	P;	Regan,	D	and	Walley,	AY.	Addiction	
Inpatient	Consultation	Service	and	Linkage	to	Outpatient	Addiction	Treatment		
American	Society	of	Addiction	Medicine	Annual	Conference	–	Baltimore,	MD,	4/2016	
	
Weinstein,	Z;	Cushman,	P;	Kazis,	L	and	Cabral,	H.	A	National	Study	of	Smoking	Cessation	
Counseling	in	Buprenorphine	Visits.	
The	Society	of	General	Internal	Medicine	National	Conference	–Hollywood,	FL	5/2016	
	 	 	 	 	 	
Weinstein,	ZM;	Cheng,	DM;	Quinn,	E;	Gryczynski,	G;	Labelle,C	and	Samet,	J.	
Psychopharmacotherapy	for	Patients	in	Primary	Care	Office	Based	Opioid	Treatment	
(OBOT)	with	Buprenorphine.		
The	Addiction	Health	Services	Research	Conference	–Marina	Del	Ray,	CA,	10/2015	
	
Weinstein,	ZM	and	Baranoski,	AS.	Risk	Factors	for	Non-Adherence	with	Routine	
Screening	Mammography	in	HIV-Infected	Women.		
The	Society	of	General	Internal	Medicine	National	Conference-	Denver,	CO.	4/2013	
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Case	Reports,	Reviews,	Chapters	and	Editorials:	
Carney,	B;	Cruz,	A;	Gapinski,	MA;	Girard,	C;	Ellenberg,	L;	Watson,	E	and	Weinstein	Z.	
Addressing	Unhealthy	Substance	Use	in	Schools:	Intro	to	SBIRT,	module	1.		Available	
online	at	Northeastern	University	School	Health	Institute,	8/2015	(Online	Media)	
	
Weinstein	ZM	and	Walley	AY.	Initiation	of	Buprenorphine	in	the	Emergency	Department	
Increased	Opioid	Treatment	Engagement	at	30	Days.	Editorial	intern	review	for	Alcohol,	
Other	Drugs	and	Health:	Current	Evidence.	Available	online	at	AOD	Health,	6/2015	
(Editorial	Internship	at	AOD	Health)		
	
